Latest Earnings Results: Q2 '26
Estimated EPS
$1.72
Reported EPS
$1.92
Surprise
+11.69%
Estimated Rev
$199.62M
Reported Rev
$199.88M
Surprise
+0.13%
• Reported GAAP EPS of -$0.46 down -221.05% YoY • Reported revenue of $199.88M up 6.32% YoY • Collegium Pharmaceutical updated its full-year 2026 guidance, now expecting product revenues between $825 million and $855 million and adjusted EBITDA between $445 million and $470 million for the full year.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $1.86 | -- | -- | N/A |
Q2 '26 | $1.72 | $1.92 | 11.69% | BEAT |
Q1 '26 | $1.52 | $1.76 | 15.49% | BEAT |
Q4 '25 | $2.13 | $2.04 | -4.19% | MISSED |
Q3 '25 | $1.86 | $2.25 | 20.97% | BEAT |